Search

Your search keyword '"Tirador, L."' showing total 18 results

Search Constraints

Start Over You searched for: Author "Tirador, L." Remove constraint Author: "Tirador, L."
18 results on '"Tirador, L."'

Search Results

1. A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function

2. Dapagliflozin and cardiovascular outcomes in type 2 diabetes

3. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

4. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

5. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

6. Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery

7. Effect of Alirocumab on Mortality After Acute Coronary Syndromes An Analysis of the ODYSSEY OUTCOMES Randomized Clinical Trial

8. Alirocumab Reduces Total Hospitalizations and Increases Days Alive and Out of Hospital in the ODYSSEY OUTCOMES Trial

9. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes

10. Cause of death and predictors of all-cause mortality in anticoagulated patients with nonvalvular atrial fibrillation: Data from ROCKET AF

11. Long-Term Use of Ticagrelor in Patients with Prior Myocardial Infarction

12. Cause of Death and Predictors of All‐Cause Mortality in Anticoagulated Patients With Nonvalvular Atrial Fibrillation: Data From ROCKET AF

13. Alogliptin after acute coronary syndrome in patients with type 2 diabetes

14. Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial

15. Effects of alirocumab on cardiovascular and metabolic outcomes after acute coronary syndrome in patients with or without diabetes: a prespecified analysis of the ODYSSEY OUTCOMES randomised controlled trial

17. Immunogenicity and safety of boosting with a recombinant two-component SARS-CoV-2 vaccine: two randomized, parallel-controlled, phase 2 studies.

18. Safety and Immunogenicity of a Recombinant Two-Component SARS-CoV-2 Protein Vaccine: Randomized, Double-Blind, Placebo-Controlled Phase I and Phase II Studies.

Catalog

Books, media, physical & digital resources